Abstract
For decades, antigen presentation on major histocompatibility complex class I for T cell-mediated immunity has been considered the primary function of proteasome-derived peptides1,2. However, whether the products of proteasomal degradation play additional parts in mounting immune responses remains unknown. Antimicrobial peptides serve as a first line of defence against invading pathogens before the adaptive immune system responds. Although the protective function of antimicrobial peptides across numerous tissues is well established, the cellular mechanisms underlying their generation are not fully understood. Here we uncover a role for proteasomes in the constitutive and bacterial-induced generation of defence peptides that impede bacterial growth both in vitro and in vivo by disrupting bacterial membranes. In silico prediction of proteome-wide proteasomal cleavage identified hundreds of thousands of potential proteasome-derived defence peptides with cationic properties that may be generated en route to degradation to act as a first line of defence. Furthermore, bacterial infection induces changes in proteasome composition and function, including PSME3 recruitment and increased tryptic-like cleavage, enhancing antimicrobial activity. Beyond providing mechanistic insights into the role of proteasomes in cell-autonomous innate immunity, our study suggests that proteasome-cleaved peptides may have previously overlooked functions downstream of degradation. From a translational standpoint, identifying proteasome-derived defence peptides could provide an untapped source of natural antibiotics for biotechnological applications and therapeutic interventions in infectious diseases and immunocompromised conditions.
| Original language | English |
|---|---|
| Pages (from-to) | 1032-1041 |
| Number of pages | 27 |
| Journal | Nature |
| Volume | 639 |
| Issue number | 8056 |
| Early online date | 5 Mar 2025 |
| DOIs | |
| Publication status | Published - 27 Mar 2025 |
Funding
We thank the members of the Merbl laboratory for their support, J. DeMartino and A. Erez for critical reading of the manuscript, E. Zisman, R. Straussman, A. Savidor, Y. Levin and B. Dassa for their support and advice. The research was supported by the European Research Council (ERC) under the European Union’s Horizon Europe research and innovation program (grant agreement no. 101045613) and the Israel Science Foundation (grant no. 2237/23). Y.M. is a CRI Lloyd J. Old STAR (CRl5602), a CRI/Israel Cancer Research Fund Technology Impact Award recipient (CRI5398) and a Cancer Research Institute/Israel Cancer Research Fund CLIP Grant (CRI4351). The Merbl laboratory is supported by Dr. Barry Sherman Institute for Medicinal Chemistry; Moross Integrated Cancer Center; EKARD Institute for Cancer Diagnosis Research; Dr. Gilbert S. Omenn and Martha A. Darling Weizmann Institute – Schneider Hospital Fund for Clinical Breakthroughs through Scientific Collaborations. A.L. is supported by the Fellowship of the Center for Integration in Science, Israel Ministry of Aliyah and Integration, P.A. is supported by a Sergio Lombroso Postdoctoral Fellowship and K.G. and R.S. are supported by Clinical Co-Mentoring fellowships through the Moross Integrated Cancer Center.
All Science Journal Classification (ASJC) codes
- General